Scholarlink

<p>Digital symptom checkers (SCs) are increasingly used to support early symptom recognition and care-seeking, yet evidence on their cost-effectiveness remains limited. We conducted an economic evaluation of a digital SC for endometriosis, a prevalent but underdiagnosed condition, as a case study. We developed a Markov decision process model to compare the digital SC with the standard of care from a societal perspective. Over a 40-year horizon, the digital SC reduced diagnostic delay by 4.36 years, generated 0.049 quality-adjusted life years (QALYs) per person, saved $5196.22 in costs, and produced an incremental net monetary benefit (INMB) of $10,089.00 at a $100,000/QALY threshold. Probabilistic sensitivity analysis confirmed the robustness of these findings, with an INMB of $12,398.92 (95% CI: $11,893.11–$12,904.72). Scenario analyses showed that the SC remained cost-effective under a wide range of assumptions, with the greatest value realized when sensitivity and specificity were ≥0.7, compliance exceeded 45%, and a time horizon of at least 10 years. This study provides the first economic evaluation of a digital SC for endometriosis and illustrates when and how digital SCs can deliver value to patients and health systems.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Economic evaluation of a digital symptom checker for endometriosis using a Markov decision process model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Yihan Xu,
  • Carley Prentice,
  • Sergio Torres-Rueda,
  • András Meczner,
  • Jan Multmeier,
  • Aidan Wickham,
  • Laura Kelly,
  • Anna Klepchukova,
  • Heorhi Stsefanovich,
  • Liudmila Zhaunova

摘要

Digital symptom checkers (SCs) are increasingly used to support early symptom recognition and care-seeking, yet evidence on their cost-effectiveness remains limited. We conducted an economic evaluation of a digital SC for endometriosis, a prevalent but underdiagnosed condition, as a case study. We developed a Markov decision process model to compare the digital SC with the standard of care from a societal perspective. Over a 40-year horizon, the digital SC reduced diagnostic delay by 4.36 years, generated 0.049 quality-adjusted life years (QALYs) per person, saved $5196.22 in costs, and produced an incremental net monetary benefit (INMB) of $10,089.00 at a $100,000/QALY threshold. Probabilistic sensitivity analysis confirmed the robustness of these findings, with an INMB of $12,398.92 (95% CI: $11,893.11–$12,904.72). Scenario analyses showed that the SC remained cost-effective under a wide range of assumptions, with the greatest value realized when sensitivity and specificity were ≥0.7, compliance exceeded 45%, and a time horizon of at least 10 years. This study provides the first economic evaluation of a digital SC for endometriosis and illustrates when and how digital SCs can deliver value to patients and health systems.